Conference Coverage

Revascularization in paraplegics best performed with PCI


 

AT THE 2018 CRT MEETING

– When paraplegics and quadriplegics have an acute MI and are candidates for revascularization, they should be treated preferentially with a percutaneous coronary intervention, according to data presented at the 2018 Cardiovascular Research Technologies meeting.

When compared 30 days after revascularization, the rates of major adverse cardiovascular events (MACE) following coronary artery bypass grafting (CABG) were 22% in the group with paraplegia or quadriplegia versus only 3.5% in those without loss of limb function. For percutaneous coronary intervention (PCI), the rates were 6% versus 2%, respectively, reported Xuming Dai, MD, PhD, an interventional cardiologist and assistant professor at the University of North Carolina at Chapel Hill.

Dr. Xuming Dai

Dr. Xuming Dai

A study of revascularization outcomes in patients with paraplegia or quadriplegia was undertaken after Dr. Dai was faced with two such patients, of whom one was ultimately referred for CABG. Concerned at the time about the suitability of CABG for patients with the potential for risk factors different from ambulatory patients, Dr. Dai consulted the literature.

“There are no guidelines, no studies. I could not even find a case report,” Dr. Dai recounted.

Pages

Recommended Reading

VIDEO: No short-term link found between PPIs, myocardial infarction
MDedge Cardiology
Overweight and obese individuals face greater cardiovascular morbidity
MDedge Cardiology
Abruptio placenta brings increased cardiovascular risk – and soon
MDedge Cardiology
Sex-triggered sudden cardiac arrest extremely rare
MDedge Cardiology
200 cardiovascular drugs now in development
MDedge Cardiology
Young diabetics are at sevenfold increased risk of sudden cardiac death
MDedge Cardiology
ACC Late-Breaking Clinical Trial sessions preview for day 1
MDedge Cardiology
ACC Day 2: Late-Breaking Clinical Trial highlights
MDedge Cardiology
Heart attacks soar in young IBD patients
MDedge Cardiology
ACC Day 3: Finishing strong in Late-Breaking Clinical Trial Sessions
MDedge Cardiology